Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immune Response to Vaccination in Tecfidera vs IFN Treated MS Subjects
NCT02097849Phase 2Completed
- Sponsor
- Biogen
- Start
- Feb 2015
- Primary completion
- May 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dimethyl fumarate in multiple sclerosis (MS) (2 arms), sponsored by Biogen. Primary endpoint: Percentage of Tetanus Responders (>= 2-Fold Rise) at Day 28 Compared to Prevaccination Level. Started Feb 2015; status: completed.
02
Drugs
dimethyl fumarate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02097849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02097849.